Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD).

Full DD Report for GLMD

You must become a subscriber to view this report.


Recent News from (NASDAQ: GLMD)

Galmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q1 2018 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2018 Earnings Conference Call May 09, 2018 08:30 AM ET Executives Bob Yedid - Investor Relations Allen Baharaff - President and Chief Executive Officer Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Officer Yohai S...
Source: SeekingAlpha
Date: May, 11 2018 16:22
Galmed beats by $0.07, misses on revenue
Galmed (NASDAQ: GLMD ): Q1 EPS of -$0.17 beats by $0.07 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 07:07
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results
TEL AVIV, Israel , May 9, 2018 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment o...
Source: PR Newswire
Date: May, 09 2018 07:00
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9
TEL AVIV, Israel , May 1, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the tre...
Source: PR Newswire
Date: May, 01 2018 08:00
Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol(TM) for NASH
TEL AVIV, Israel , April 16, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatme...
Source: PR Newswire
Date: April, 16 2018 07:00
Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results
Note: The Total Pharma Tracker will present a discussion session with Geron author MedTechBio on April 5 at 9am EST in our members-only chatroom. Everyone can participate for free by joining our Free Trial . Analysis focus: Geron Geron (NASDAQ: GERN ) shares have surged more tha...
Source: SeekingAlpha
Date: April, 04 2018 08:00
Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering
TEL AVIV, Israel , April 3, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy f...
Source: PR Newswire
Date: April, 03 2018 07:00
Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
TEL AVIV, Israel , March 27, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the tr...
Source: PR Newswire
Date: March, 27 2018 07:00
Key events next week - healthcare
Noteworthy events for the week of March 18 - 24 for healthcare investors: More news on: Spark Therapeutics, SELLAS Life Sciences Group, Inc., Atara Biotherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 16 2018 10:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-2111.2911.8012.0111.29168,625
2018-08-2011.5111.3411.7511.20111,987
2018-08-1711.5511.460111.619811.3475,417
2018-08-1611.2611.5511.8011.15132,734
2018-08-1511.0011.2211.4210.88232,085

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2140,62852,33177.6366Short
2018-08-2028,89742,17068.5250Short
2018-08-1718,43633,27255.4100Short
2018-08-1645,38461,18974.1702Short
2018-08-1545,54774,01761.5359Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GLMD.


About Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)

Logo for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $95,317,776 - 05/16/2018
    • Authorized: 50,000,000 - 05/01/2018
    • Issue and Outstanding: 15,473,665 - 05/01/2018

     


    Recent Filings from (NASDAQ: GLMD)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 09 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: April, 16 2018
    Prospectus filed under Rule 424(b)(5)
    Filing Type: 424B5Filing Source: edgar
    Filing Date: April, 04 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 04 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 03 2018
    Registration statement for certain foreign private issuers offered for certain transactions
    Filing Type: F-3Filing Source: edgar
    Filing Date: March, 26 2018
    Annual and transition report of foreign private issuers under sections 13 or 15(d)
    Filing Type: 20-FFiling Source: edgar
    Filing Date: March, 13 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 13 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 07 2018

     

     


    Daily Technical Chart for (NASDAQ: GLMD)

    Daily Technical Chart for (NASDAQ: GLMD)


    Stay tuned for daily updates and more on (NASDAQ: GLMD)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: GLMD)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GLMD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GLMD and does not buy, sell, or trade any shares of GLMD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/